Acular LS is generally used to help manage symptoms related to inflammatory and irritative states in the eye, providing focused symptomatic relief. The medication is primarily relevant for easing specific types of ocular discomfort.

It is applied across domains where additional symptomatic support is needed, primarily addressing acute pain and intense, localized symptoms such as burning and stinging associated with corneal refractive surgery recovery. The medicine is also relevant for easing symptoms that create noticeable physiological strain, like pronounced light sensitivity (photophobia), and intense ocular itching associated with conditions like seasonal allergic conjunctivitis.

Quick Fact: Relief for Acute Pain

“Acular LS is commonly used in clinical settings that involve acute or unstable symptom patterns, supporting patients during difficult episodes by easing distress.”

Its use during these symptomatic phases helps ease the overall symptom burden and assists with maintaining functional stability, contributing to improved comfort during periods of heightened symptoms.

Regulatory References

1. DailyMed: Ketorolac Tromethamine Ophthalmic Solution, 0.4% Indications

Who Can and Cannot Use Acular LS?

The population eligibility for Acular LS (ketorolac tromethamine ophthalmic solution 0.4%) is strictly governed by regulatory classifications, defining who may use the medicine and who must avoid it.

Contraindicated and Restricted Populations

Classification	Population Restriction (Official Statement)
Absolute Contraindication	Patients with a demonstrated hypersensitivity to any ingredient in the formulation or known cross-sensitivity to aspirin or other NSAIDs (Nonsteroidal Anti-Inflammatory Drugs).
Pediatric Restriction	Not established for use in children younger than 3 years old. Use is permitted for patients 3 years of age and older.
Pregnancy/Lactation	Contraindicated during late pregnancy (third trimester) due to risk to the fetal cardiovascular system. Should not be used during breast-feeding.
Conditional Caution	Use requires special caution in patients with pre-existing conditions that increase ocular risk, such as diabetes mellitus, rheumatoid arthritis, ocular surface diseases, or a history of complicated ocular surgeries.

Additional Eligibility Constraints

Adults and older adult patients are generally eligible, with no overall difference in safety noted for geriatric individuals. The medicine must not be administered while wearing contact lenses, and use should be monitored in patients with known bleeding tendencies or conditions susceptible to delayed healing.

Interactions with other medicines and products

The official interaction profile for Acular LS (ketorolac tromethamine ophthalmic solution) is defined by its topical application, which results in minimal systemic absorption. Consequently, regulatory documents focus on local effects and administration constraints rather than systemic metabolic interactions.

Official Interaction Statements

Interaction Type	Interacting Substance/Class	Official Documented Outcome
Pharmacodynamic Risk	Topical Corticosteroids	Co-administration may increase the risk of delayed or complicated corneal wound healing by contributing to additive local effects.
Pharmacodynamic Risk	Systemic Medications that Prolong Bleeding Time (e.g., anticoagulants, antiplatelet agents)	Use requires caution, especially in the context of ocular surgery, due to the documented potential for increased bleeding of ocular tissues.
Administration Timing	Other Topical Ophthalmic Medications	Drops must be administered with at least a 5-minute separation to prevent the second drug from washing out the Acular LS and diminishing its efficacy.

No significant pharmacokinetic interactions involving CYP enzymes or drug transporters are documented in official prescribing information for the ophthalmic formulation due to its low systemic exposure. Additionally, regulatory information advises caution regarding use in late pregnancy due to the known effects of prostaglandin-inhibiting drugs on the fetal cardiovascular system.

Ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), functions through the non-selective inhibition of the cyclooxygenase (COX) enzyme.

This interaction occurs in the cytoplasm and involves competitive binding at the active site of both COX-1 and COX-2 isoforms. Inhibition of these enzymes interrupts the arachidonic acid cascade, blocking the metabolic conversion of the fatty acid substrate into eicosanoids.

The downstream cascade consequence is a reduced rate of biosynthesis and subsequent cellular release of pro-inflammatory mediators, primarily prostaglandins. This action modulates the local concentration of lipid signaling molecules, specifically resulting in a decrease in prostaglandin E2 (PGE2) levels within the targeted ocular tissues. This physiological modulation is the molecular basis of the drug's effect.

Acular LS (ketorolac tromethamine ophthalmic solution, 0.4%) is an eye drop solution used to reduce ocular pain, burning, and stinging following corneal refractive surgery.

Recommended Dosage

The typical recommended dose is one drop instilled into the affected eye(s) four times a day (QID) as needed for up to four days following the surgery. Always use the medication exactly as directed by a healthcare professional.

Condition	Dose	Frequency	Duration
Post-Corneal Refractive Surgery Pain/Stinging	One drop in operated eye(s)	4 times daily (QID)	Up to 4 days, as needed

Administration Instructions

1. Hand Hygiene: Wash your hands thoroughly before administering the drops.
2. Preparation: Tilt your head back, look up, and pull down the lower eyelid to create a small pouch.
3. Application: Hold the dropper tip directly over the eye without touching it. Instill one drop into the pouch. Avoid letting the dropper tip touch the eye or any surrounding surface to prevent contamination, which may lead to serious eye infection.
4. Absorption: Close the eye gently for one to two minutes. Do not rub or blink. Pressing gently on the inner corner of the eye near the nose for about one minute may help prevent the drop from draining out.
5. Contact Lenses: Do not administer this solution while wearing soft contact lenses. Consult a healthcare provider regarding when you may safely resume wearing them.
6. Multiple Medications: If you are using more than one topical ophthalmic medication, drops should be administered at least five minutes apart to ensure proper absorption.

Research Evidence / Overview of Studies for Acular LS

This section provides a summary of the types of research and clinical evaluations that have been conducted for Acular LS (ketorolac 0.4%), based on information from official regulators and peer-reviewed scientific literature. The goal is to describe the available evidence without offering medical advice, treatment recommendations, or certainty about individual outcomes.

---

Evidence for Use in Post-Surgical Ocular Pain

The clinical evaluation for this ophthalmic solution involves short-term randomized controlled trials (RCTs). These studies included adult populations who had undergone corneal refractive surgery, such as Photorefractive Keratectomy (PRK). Research explored outcomes related to physical discomfort, evaluating patterns of acute pain experienced. Trials reported measurements of subjective pain intensity and symptom severity, describing the patterns observed in the study population during the immediate recovery phase.

The evidence is predominantly focused on the short-term, typically limited to the first few days after the procedure. This means that while research provides insight into short-term changes, there is limited information for long-term outcomes or how patterns of pain and discomfort evolve over many months.

---

Studies Examining Symptoms in Allergic Conjunctivitis and Post-Cataract Inflammation

Research has examined the medicine's activity in conditions characterized by periods of heightened symptoms, such as seasonal allergic conjunctivitis. These studies included comparative evaluations of the 0.4% solution against a vehicle and the older, higher-concentration 0.5% formulation. Studies examined outcomes related to inflammatory or irritative states, such as ocular itching scores and visible signs of inflammation (for allergy) or swelling and cellular presence (for post-cataract inflammation).

The level of certainty remains limited for this specific 0.4% concentration because few dedicated trials were conducted solely on the low-strength formulation for these indications. Furthermore, the evidence is largely restricted to short-term assessment; data for sustained control over chronic or seasonal issues are generally insufficient.

---

Gaps and Uncertainty in the Research Landscape

A primary limitation is the short-term focus of most studies, providing minimal data on long-term effects. There is also limited information for pediatric patients or older adults who may have comorbid conditions. The research relies on comparative evidence to support the use of the 0.4% concentration for certain indications where the 0.5% formulation has a more extensive, dedicated research history.

Common questions about Acular LS (FAQ)

Q: What is the main difference between Acular LS and other common eye drops?

Official labeling clarifies that Acular LS is classified as an ophthalmic Nonsteroidal Anti-Inflammatory Drug (NSAID). This indicates its core purpose is to reduce pain and inflammation by blocking the body's natural synthesis of inflammatory mediators. This mechanism is distinct from that of drops intended solely for lubrication or to treat microbial infections.

---

Q: Is Acular LS a steroid eye drop?

Acular LS is an NSAID (Nonsteroidal Anti-Inflammatory Drug). Its chemical structure and pharmacological classification differ from those of corticosteroids (steroids). The medicine is noted for providing anti-inflammatory action without containing steroidal compounds.

---

Q: Can Acular LS be used for dry eye?

According to official product information, Acular LS is indicated only for the reduction of ocular pain and burning/stinging following corneal refractive surgery. Official labeling defines its use only for this specific purpose, and dry eye is not listed as an approved indication.

---

Q: Does Acular LS contain preservatives?

Yes, official formulation details indicate that the solution contains benzalkonium chloride as a preservative. This substance is included to help inhibit microbial growth in the bottle after opening, maintaining the sterility of the drops.

---

Q: Is it safe to drive after using Acular LS?

Regulatory documents advise caution when performing tasks that require clear vision. Ophthalmic NSAIDs may cause temporary blurred vision or other visual changes immediately after instillation. Patients are advised in the labeling to wait until their vision clears before driving or operating machinery.

---

Q: Does Acular LS have any effect on eye pressure?

The official information notes that studies indicate the active ingredient, ketorolac tromethamine, has no significant effect on intraocular pressure (IOP). This finding is based on clinical study results.

---

Q: Are there any food or drink restrictions while using Acular LS?

Due to the medicine's minimal systemic absorption when applied as an eye drop, the official prescribing information does not list any warnings or restrictions related to specific foods or drinks.

---

Q: Can I share my bottle of Acular LS with someone else?

Official administration instructions emphasize preventing contamination of the dropper tip to avoid the risk of eye infection. For this reason, the container is generally intended for single-patient use only, and should not be used by multiple people.

---

Q: Is blurred vision a temporary side effect of Acular LS?

Blurred vision has been reported as an adverse effect in postmarketing experience with this medicine. As with many eye drop solutions, this effect is often temporary and may be experienced shortly after the drops are administered.

---

Q: What happens if Acular LS gets into my mouth or nose?

Overdose is considered unlikely to occur from accidental administration outside the eye. In cases of accidental exposure or ingestion, some regulatory materials refer to general dilution procedures.

---

Q: Is it possible to become dependent on Acular LS?

Official drug class information indicates that, as an NSAID, the medicine is not classified with drug classes that carry a risk of physical dependence or tolerance.

---

Q: What does 'tromethamine' do in the Acular LS formulation?

Tromethamine is an ingredient included in the medicine as a buffering agent. It is compounded with the active drug to form a salt and primarily functions to adjust the pH of the solution, which helps to maintain the medicine's stability and comfort upon application.

---

Q: What if I accidentally use more than the recommended amount of Acular LS?

The risk of systemic overdose is considered unlikely due to the low concentration and topical application to the eye. Symptoms following acute NSAID overdoses are generally described in regulatory information as limited to mild gastrointestinal or nervous system effects.

How to Store and Dispose of Acular LS?

ACULAR LS (ketorolac tromethamine ophthalmic solution) must be stored at controlled room temperature, specifically between 15 C to 25 C (59 F to 77 F). The medicine must not be frozen.

Storage Requirements

The product must be kept out of the sight and reach of children for safety. It is necessary to store in the original container and keep the cap tightly closed. The solution should be protected from light, as the active substance is known to discolor upon prolonged exposure.

Disposal

Official regulations require that any unused or expired ACULAR LS be disposed of in accordance with local requirements. Medicines must not be thrown away via wastewater, such as a sink or toilet.